Trial · NCT00664521
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Rituximab Plus Atacicept | AEs | 17 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Rituximab Plus Placebo | AEs | 9 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Rituximab Plus Atacicept | SAEs | 6 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Rituximab Plus Placebo | SAEs | 2 | Participants | |
| Percentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L) | Rituximab Plus Atacicept | 0 | percentage of participants | ||
| Percentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L) | Rituximab Plus Placebo | 0 | percentage of participants | ||
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Atacicept | Systolic Blood Pressure (n = 12, 9) | 3.74 | Standard Deviation 11.76 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Placebo | Systolic Blood Pressure (n = 12, 9) | -6.29 | Standard Deviation 13.80 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Atacicept | Diastolic Blood Pressure (n = 12, 9) | 1.09 | Standard Deviation 11.19 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Placebo | Diastolic Blood Pressure (n = 12, 9) | 4.89 | Standard Deviation 10.09 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Atacicept | Pulse (n = 12, 9) | 10.21 | Standard Deviation 19.93 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Placebo | Pulse (n = 12, 9) | -8.54 | Standard Deviation 11.98 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Atacicept | Temperature (n = 10, 8) | 0.23 | Standard Deviation 1.05 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Placebo | Temperature (n = 10, 8) | -0.44 | Standard Deviation 0.86 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Atacicept | RBC (n = 12, 9) | 3.10 | Standard Deviation 5.30 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Placebo | RBC (n = 12, 9) | 4.94 | Standard Deviation 7.18 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Atacicept | Hemoglobin (n = 12, 9) | 2.55 | Standard Deviation 5.32 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Placebo | Hemoglobin (n = 12, 9) | 4.93 | Standard Deviation 6.18 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Atacicept | Hematocrit (n = 12, 9) | 2.39 | Standard Deviation 6.30 | Percent change |
| Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32 | Rituximab Plus Placebo | Hematocrit (n = 12, 9) | 6.05 | Standard Deviation 6.15 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00664521/results